Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Cancer Monoclonal Antibodies Market – Growth, Trends, and Forecast (2019 – 2024)” report has been added to ResearchAndMarkets.com’s…
Pfizer got approval for Trazimera n USA for the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 adenocarcinoma.
The U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of the Mylan’s and Biocon’s proposed biosimilar trastuzumab.
Mylan has agreed to the terms of a global settlement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. related to patents for Herceptin (trastuzumab), which provides Mylan with global licenses for its trastuzumab product.